BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35617560)

  • 1. FDA Evaluating Possible Serious Risks From Umbralisib.
    Aschenbrenner DS
    Am J Nurs; 2022 Jun; 122(6):23. PubMed ID: 35617560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
    Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
    Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
    Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
    Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Umbralisib: First Approval.
    Dhillon S; Keam SJ
    Drugs; 2021 May; 81(7):857-866. PubMed ID: 33797740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Lunning M; Vose J; Nastoupil L; Fowler N; Burger JA; Wierda WG; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Sportelli P; Miskin HP; Weiss MS; O'Brien S
    Blood; 2019 Nov; 134(21):1811-1820. PubMed ID: 31558467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
    Davids MS; O'Connor OA; Jurczak W; Samaniego F; Fenske TS; Zinzani PL; Patel MR; Ghosh N; Cheson BD; Derenzini E; Brander DM; Reeves JA; Knopińska-Posłuszny W; Allan JN; Phillips T; Caimi PF; Lech-Maranda E; Burke JM; Agajanian R; Pettengell R; Leslie LA; Cheah CY; Fonseca G; Essell J; Chavez JC; Pagel JM; Sharman JP; Hsu Y; Miskin HP; Sportelli P; Weiss MS; Flinn IW
    Blood Adv; 2021 Dec; 5(23):5332-5343. PubMed ID: 34547767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
    Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
    Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evidence to date on umbralisib for the treatment of refractory marginal zone lymphoma and follicular lymphoma.
    Schweitzer J; Hoffman M; Graf SA
    Expert Opin Pharmacother; 2022 Apr; 23(5):535-541. PubMed ID: 35209784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
    Fowler NH; Samaniego F; Jurczak W; Ghosh N; Derenzini E; Reeves JA; Knopińska-Posłuszny W; Cheah CY; Phillips T; Lech-Maranda E; Cheson BD; Caimi PF; Grosicki S; Leslie LA; Chavez JC; Fonseca G; Babu S; Hodson DJ; Shao SH; Burke JM; Sharman JP; Law JY; Pagel JM; Miskin HP; Sportelli P; O'Connor OA; Weiss MS; Zinzani PL
    J Clin Oncol; 2021 May; 39(15):1609-1618. PubMed ID: 33683917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible Increased Risk of Death from Blood Cancer Drug.
    Aschenbrenner DS
    Am J Nurs; 2022 Oct; 122(10):20-21. PubMed ID: 36136021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Umbralisib and ublituximab: an upcoming regimen for chronic lymphocytic leukemia.
    Gribben J
    Clin Adv Hematol Oncol; 2021 Dec; 19(12):768-769. PubMed ID: 34928931
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
    Mato AR; Ghosh N; Schuster SJ; Lamanna N; Pagel JM; Flinn IW; Barrientos JC; Rai KR; Reeves JA; Cheson BD; Barr PM; Kambhampati S; Lansigan F; Pu JJ; Skarbnik AP; Roeker L; Fonseca GA; Sitlinger A; Hamadeh IS; Dorsey C; LaRatta N; Weissbrot H; Luning Prak ET; Tsao P; Paskalis D; Sportelli P; Miskin HP; Weiss MS; Svoboda J; Brander DM
    Blood; 2021 May; 137(20):2817-2826. PubMed ID: 33259589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
    Keating GM
    Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody therapy for lymphoma.
    Campbell P; Marcus R
    Blood Rev; 2003 Sep; 17(3):143-52. PubMed ID: 12818224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
    Lemery SJ; Zhang J; Rothmann MD; Yang J; Earp J; Zhao H; McDougal A; Pilaro A; Chiang R; Gootenberg JE; Keegan P; Pazdur R
    Clin Cancer Res; 2010 Sep; 16(17):4331-8. PubMed ID: 20601446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
    Roskoski R
    Pharmacol Res; 2021 Jun; 168():105579. PubMed ID: 33774181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.